Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2017

View Archived Issues

AAV-mediated liver delivery of secretable GAA improves long-term survival in Pompe disease mice

Tasigna receives approval in Japan for treatment of pediatric chronic myeloid leukemia

SK Chemicals launches SKYZoster shingles vaccine in South Korea

Pfizer enrolling participants in phase I study of PF-06863135

Clover Biopharmaceuticals receives approval to initiate clinical trials of SCB-808 in China

FDA accepts NDA for OTX-101

Maruho and RaQualia enter worldwide license agreement

Celgene researchers report compounds with antiprotozoal activity

Agents for the treatment of malaria described in Celgene patent

P2X7 receptor antagonists for pain reported in Shionogi patent

Beijing Jacobio Pharmaceuticals patents SHP-2 inhibitors

Pramana Pharmaceuticals patent describes glucose-dependent insulinotropic receptor agonists

Lilly initiates phase II study of LY-3002813 and LY-3202626 in early symptomatic Alzheimer's disease

Athenex receives U.K. promising innovative medicine designation for Oraxol

Combination therapy with gedatolisib shows promising preliminary antitumor activity in breast cancer

Kaiso as a potential new biomarker and therapeutic target in TNBC

NeuroRx enters agreement for clinical trial of NRX-100/NRX-101 regimen

Phase II data show safety of combining Ra-223 with hormonal therapy and denosumab

Phase III SIERRA study of Iomab-B cleared to continue enrollment

Phase II safety data for abemaciclib as treatment of brain metastases secondary to HR+ breast cancer

First patient enrolled in phase III OVAL study of VBL Therapeutics' VB-111

Keytruda approved for new indication in Japan

Innovation Pharmaceuticals reports preliminary data from phase IIa study of Kevetrin

Protalix Biotherapeutics' pegunigalsidase alfa granted orphan drug status in E.U.

New phase III trial explores use of TSC in newly diagnosed GBM

CFDA designates lenvatinib for priority review and approval for HCC

Bayer initiates phase III studies in Japan of molidustat in nondialysis patients with renal anemia

Eli Lilly's Zyprexa approved for chemotherapy-induced nausea and vomiting in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...